Want to see JP:4599 full AI Analyst Report?
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:40Underperform
Price Target:
¥152.00
▼(-40.39% Downside)
Action:Reiterated
Date:09/12/26
The score is driven primarily by very weak financial performance (zero revenue in 2024–2026, large losses, and sustained negative free cash flow), which raises funding/runway risk despite a low-debt balance sheet. Technicals add further pressure, with the price far below key moving averages and bearish momentum. Valuation does not offset these risks because the negative P/E reflects ongoing losses and there is no dividend yield support.
Positive Factors
Low Financial Leverage
An essentially debt-free balance sheet limits leverage and interest-burden risk, preserving more flexibility than a highly indebted structure. This provides some capacity to manage losses or pursue operations without immediate pressure from lenders, although capital erosion remains a concern.
Negative Factors
Revenue Has Fallen to Zero
Zero reported revenue across three consecutive years indicates a severe breakdown in commercial activity and leaves no current top-line base from which to fund operations. Without renewed revenue generation, the company remains dependent on its balance sheet or external funding to sustain the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
An essentially debt-free balance sheet limits leverage and interest-burden risk, preserving more flexibility than a highly indebted structure. This provides some capacity to manage losses or pursue operations without immediate pressure from lenders, although capital erosion remains a concern.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.28B
Dividend YieldN/A
Average Volume (3M)592.35K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth4.68%
CountryJP
Employees45
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.69
Shares Outstanding62,681,200
10 Day Avg. Volume335,420
30 Day Avg. Volume592,350
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.26
Price to Sales (P/S)0.00
P/FCF Ratio-11.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently under...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
24
Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.35B | 22.98M |
| Gross Profit | -38.36M | -49.50M | -44.35M | 2.30B | 22.98M |
| EBITDA | -1.96B | -1.92B | -2.03B | 190.18M | -1.93B |
| Net Income | -1.85B | -1.93B | -2.02B | 168.35M | -1.95B |
Balance Sheet | |||||
| Total Assets | 5.91B | 7.52B | 9.09B | 10.72B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 5.38B | 6.99B | 8.41B | 10.22B | 8.88B |
| Total Debt | 0.00 | 0.00 | 0.00 | 531.00K | 3.67M |
| Total Liabilities | 196.04M | 210.27M | 194.06M | 348.51M | 207.74M |
| Stockholders Equity | 5.71B | 7.31B | 8.89B | 10.37B | 9.40B |
Cash Flow | |||||
| Free Cash Flow | -1.62B | -1.46B | -1.88B | 1.14B | -1.40B |
| Operating Cash Flow | -1.61B | -1.41B | -1.88B | 1.14B | -1.40B |
| Investing Cash Flow | -3.21B | -42.50M | -4.78M | -344.00K | -330.00K |
| Financing Cash Flow | 0.00 | 41.25M | 78.97M | 202.60M | 112.86M |
StemRIM Inc. Technical Analysis
Negative
255.00
Price Trends
269.52
Negative
283.91
Negative
288.06
Negative
Market Momentum
-33.22
Negative
24.78
Positive
20.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Negative. The current price of 255 is above the 20-day moving average (MA) of 182.10, below the 50-day MA of 269.52, and below the 200-day MA of 288.06, indicating a bearish trend. The MACD of -33.22 indicates Negative momentum. The RSI at 24.78 is Positive, neither overbought nor oversold. The STOCH value of 20.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.17B | 62.37 | ― | 1.61% | -9.94% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ¥40.93B | 59.48 | ― | ― | -47.32% | ― | |
46 Neutral | ¥32.20B | -72.14 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥13.51B | -28.32 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.34B | -7.18 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥10.28B | -5.39 | ― | ― | ― | 4.68% |
* General Sector Average
JP:4599
StemRIM Inc.
163.00
-126.00
-43.60%
JP:4593
Healios KK
296.00
-172.00
-36.75%
JP:4880
CellSource Co., Ltd.
319.00
-203.75
-38.98%
JP:4978
ReproCELL Inc.
127.00
-48.00
-27.43%
JP:7774
Japan Tissue Engineering Co., Ltd.
801.00
315.00
64.81%
JP:7776
CellSeed Inc.
207.00
-259.00
-55.58%
StemRIM Inc. Corporate Events
StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease
Oct 7, 2026
StemRIM Inc. has secured a U.S. patent for a stem cell gene therapy technology, development code SR-GT1, designed as a curative treatment for recessive dystrophic epidermolysis bullosa. The invention covers the therapeutic use of autologous mesenc...
StemRIM Plans Zero-Cost Stock Options to Align Talent With Long-Term Growth
Sep 25, 2026
StemRIM Inc. has proposed issuing up to 8,000 stock options, in the form of new share subscription rights, free of charge to executive officers, employees, and approved external collaborators, subject to shareholder approval at its October 20th an...
StemRIM Strengthens Governance Ahead of Growth Drive
Sep 25, 2026
StemRIM Inc. has nominated a slate of five directors, including one new outside director, to be approved at its October 28, 2026 annual shareholders meeting, as the terms of all current directors expire. The proposed expansion of the board by one ...
StemRIM Secures South Korean Patent for Redasemtide in Cartilage Disorders
Sep 25, 2026
StemRIM Inc., a biotech venture from The University of Osaka, is developing drug-based regenerative therapies that activate the body’s own mesenchymal stem cells to repair damaged tissues rather than relying on cell transplantation. Its flag...
StemRIM Grants New Stock Options to Directors as Regenerative Medicine Pipeline Advances
Sep 10, 2026
StemRIM Inc. has set final terms for its 20th series of stock acquisition rights, issuing 3,000 stock option units to four directors, representing rights to acquire 300,000 common shares at an exercise price of 24,500 yen per unit. The move unders...
StemRIM Sets Terms for New Employee Stock Option Issuance
Sep 10, 2026
StemRIM Inc. has approved detailed terms for its 19th series of stock acquisition rights to be granted as stock options to employees, issuing 4,989 units corresponding to 498,900 common shares. The options, allocated to 47 employees at an exercise...
StemRIM Deepens Losses but Secures Funding for Regenerative Medicine Push
Sep 9, 2026
StemRIM Inc. reported another year of operating losses for the fiscal year ended July 31, 2026, with net income remaining in the red and equity per share declining as total assets and net assets fell. Cash and cash equivalents dropped sharply as o...
StemRIM Issues New Director Stock Options With Limited Dilution
Sep 9, 2026
StemRIM Inc. has approved the issuance of its 20th series of stock acquisition rights as stock options to directors, under a previously sanctioned remuneration framework that caps annual stock option value for directors and corporate auditors. The...
StemRIM Issues New Employee Stock Options With Limited Dilution Impact
Sep 9, 2026
StemRIM Inc. has approved the issuance of its 19th series of stock acquisition rights as stock options to employees, with up to 4,989 units convertible into 498,900 shares of common stock. The options, issued without payment and exercisable betwee...
StemRIM Secures South Korean Patent for Gene Therapy Targeting Rare Skin Disease
Aug 3, 2026
StemRIM Inc. said it has secured patent protection in South Korea for its stem cell gene therapy technology SR-GT1, designed as a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in type ...
StemRIM Wins Mexican Patent for Redasemtide Cartilage Therapy
Jul 22, 2026
StemRIM Inc. said it will soon secure a patent in Mexico for using its peptide drug Redasemtide as a therapeutic agent for cartilage disorders, including traumatic defects, osteoarthritis and osteochondritis dissecans. The patent, filed jointly wi...
StemRIM Secures Canadian Patent for Regenerative Heart Drug Redasemtide
Jul 13, 2026
StemRIM Inc. said a medical use patent for its Regeneration-Inducing Medicine candidate Redasemtide, covering cardiomyopathy, old myocardial infarction and chronic heart failure, is set to be registered in Canada, adding to existing protection in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.